

10 October 2017 EMA/359806/2017 Human Medicines Research and Development Support

EMA expert meeting on genome editing technologies used in medicinal product development

18 October 2017
European Medicines Agency, London, United Kingdom

Meeting room 2F



Objectives of the meeting

The European Medicines Agency (EMA) is convening an expert meeting (invitation only) on 18 October 2017 with the aim to discuss scientific and regulatory opportunities and challenges of medicinal product development using genome editing technologies.

Programme overview

Sessions

Session 1: Genome editing and technologies: state of the art and future outlook

Session 2: Application of genome editing by Academia

Session 3: Case studies using genome editing technologies: CRISPR-Cas9, TALENs and Zinc finger

nucleases

Organising Committee

Committee for Advance Therapy (CAT)

Martina Schüßler-Lenz CAT Chair, Paul-Ehrlich-Institute (PEI), Germany

Bernd Gänsbacher CAT member, Technical University Munich, Germany

Paolo Gasparini CAT member, University of Trieste, Italy

Toivo Maimets CAT member, University of Tartu, Estonia

Asterios Tsiftsoglou CAT member, Aristotle University of Thessaloniki, Greece

Maura O'Donovan CAT member, Health Products Regulatory Authority (HPRA), Ireland

Dariusz Śladowski CAT member, Medical University of Warsaw, Poland

Simona Badoi CAT member, National Agency for Medicines and Medical Devices (ANM),

Romania

Metoda Lipnik-

Stangelj

CAT member, University of Ljubljana, Slovenia

CAT member, Medicines and Healthcare Products Regulatory Agency

Niederlaender (MHRA), United Kingdom

Belaïd Sekkali CAT alternate, Federal Agency for Medicines and Health Products (AFMPS-

FAGG), Belgium

Margarida Menezes-

Ferreira

CAT member, National Authority of Medicines and Health Products

(INFARMED), Portugal

Egbert Flory CAT alternate, Paul-Ehrlich-Institute (PEI), Germany

Rune Kjeken CAT alternate, Norwegian Medicines Agency (NOMA), Norway

Marcos Timón CAT alternate, Spanish Agency of Medicines and Medical Devices (AEMPS),

Spain

Michele Lipucci CAT alternate, European Organisation for Rare Diseases (Eurordis), Italy

Tiina Palomäki Expert, Finnish Medicines Agency (FIMEA), Finland

Silke Schuele Expert, Paul-Ehrlich-Institute (PEI), Germany

Pharmacogenomics Working Party (PGWP)

Krishna Prasad PGWP Chair, Medicines and Healthcare Products Regulatory Agency

(MHRA), United Kingdom

Magnus Ingelmann-

Sundberg

PGWP Additional Expert, Karolinska Institute, Sweden

European Medicines Agency (EMA)

Falk Ehmann Science and Innovation – Product Development Scientific Support

Patrick Celis Scientific Committees Secretariat, CAT secretariat

Lucia D'Apote SCiRS - Scientific Committee Regulatory Science Strategy

Lorenza Rattazzi Scientific Committees Secretariat, CAT and COMP secretariat

Marie-Hélène Pinheiro Lïaison officer - Corporate Stakeholders

Programme

9:20-9:50 Registration

Registration and badge collection at the reception on the ground floor.

7.50-10.00 Welcome and opening	9:50-10:00	Welcome and opening
--------------------------------	------------	---------------------

EMA: Guido Rasi, Executive Director

10:00-10:30 Session 1: Genome editing and technologies: state of the art and future outlook

Chair: Krishna Prasad, PGWP Chair

Genome editing - state of the art and future outlook
 Shengdar Tsai, St Jude Children's Research Hospital – Memphis, US (followed by Q&A)

Discussion on summary of comments

10:30-12:30 Session 2: Application of Genome editing by Academia

Chair: Paolo Gasparini, CAT member

 CRISPR in drug discovery and development - achievements, opportunities and challenges

Presented by Volker Lauschke, Karolinska Institute, Stockholm, (SE)

 Specificity of genome editing tools - detection methods and ON/OFF target modifications

Presented by Richard Gabriel, *National Center for Tumor Diseases (NCT)*, *Heidelberg*, *(DE)*

 Towards clinical translation of hematopoietic stem cell genome editing for the treatment of inherited diseases

Presented by Pietro Genovese, San Raffaele Hospital, Milan, (IT)

Clinical trials using CRISPR-Cas

Presented by Bernd Gänsbacher, CAT member

Questions and Answers session

12:30 Lunch break

13:30-16:00 Session 3: Case studies using genome editing technologies: CRISPR-Cas9, TALENs and Zinc finger nucleases

Chair: Martina Schüßler-Lenz, CAT Chair

 Case study 1 - A case study for developing a genomic medicine to treat an inherited retinal dystrophy

Presented by Vic Myer, Editas Medicines

 Case study 2 - Ex vivo genome editing with CRI SPR-Cas9 to treat serious diseases

Presented by Bill Lundberg, CRISPR Therapeutics

 Case study 3 - Realizing the potential of CRISPR-Cas9 technology for therapeutic applications

Presented by Sean Burns, Intellia

 Case study 4 - Preclinical studies to support the clinical translation of ZFN-based Genome editing

Presented by Michael Holms, Sangamo Therapeutics

 Case study 5 – Development of TALEN-edited allogeneic CAR-T cell therapies

Presented by Julianne Smith, Cellectis

 Case study 6 – Scientific and regulatory considerations for the development of megaTAL genome editing products for the treatment of cancer and severe genetic diseases

Presented by Philip Gregory, Bluebird Bio

Questions and Answers session

16:00 Coffee break

16:15-17:00 Roundtable discussion

All speakers and sessions' chairs

17:00 Closing remarks by the chairs

Travel and Accommodation

Participants must possess valid travel documents and, where relevant, a visa for entry into the United Kingdom. Should you require an official letter of invitation, please contact PGWPSecretariat@ema.europa.eu.

Recording and Photography

The Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency as enshrined in the Treaty on the European Union. The conference will be recorded. By attending these events you consent to any photographing, recording, broadcast and publication of presentations on the EMA website.

WiFi access


WiFi is available throughout the EMA. Login details can be found on the back of your EMA access pass.

Getting to Canary Wharf

The EMA is located in Canary Wharf, a business district in the east of London.

Please find below the public transport options for travelling to Canary Wharf together with the approximate journey times and the map of the area.

Directions to European Medicines Agency and map of the area



By Docklands Light Railway (DLR)

Both venues are a short walk from Canary Wharf or Heron Quays station on the DLR. Services run from Bank, Tower Gateway, Lewisham, Stratford, King George V and Beckton.

By Underground

The nearest stop for both venues is Canary Wharf station on the Jubilee Line. From East exit (NB. This is the closest exit to 30 Churchill Place): exit the station and turn left into Upper Bank Street, turn right at Canada Square and continue straight into Churchill Place.

By Bus

Canary Wharf is serviced by local bus numbers D3, D7, D8, 135 and 277.

River services

River services run between Embankment, London Bridge and Canary Wharf throughout the day. Canary Wharf pier is roughly a 15-minute walk from the European Medicines Agency.

From London City Airport

Take DLR City Airport to Canary Wharf (journey time is around 20 minutes).

From Gatwick Airport

Take a mainline train to London Bridge, then the Jubilee Line to Canary Wharf (journey time around 50 minutes).

From Heathrow Airport

Take the London underground Piccadilly Line to Green Park, change to the Jubilee Line to Canary Wharf (journey time around 1hr 20 minutes).

Alternatively, take the Heathrow Express train to Paddington, then the Circle or Bakerloo line to Baker Street, then the Jubilee Line to Canary Wharf (journey time around 1hr 20 minutes).

Alternatively, you can take the Heathrow Express train to Paddington, then the District or Circle Line to Tower Hill then the Docklands Light Railway (DLR) to Canary Wharf (journey time around 1hr 30 minutes).

From Stansted Airport

Take the Stansted Express to London Liverpool Street then the Circle Line to Tower Hill and change onto the DLR to Canary Wharf (journey time around 70 minutes).

From Luton Airport

Take a first Capital Connect train to London Bridge then the Jubilee Line to Canary Wharf (journey time around 60 minutes).

From St Pancras International train station

Take the Northern Line to London Bridge then the Jubilee Line to Canary Wharf (journey time around 45 minutes).

Contact

Should you have any questions, please contact Monica Simeoni or Falk Ehmann via PGWPSecretariat@ema.europa.eu.

Useful links

http://www.tfl.gov.uk/

National Rail

Gatwick Express

Heathrow Express

Stansted Express

Eurostar

Heathrow Airport

Gatwick airport

London City

London Stansted